Differentially Expressed MicroRNAs in Conservatively Treated Nontraumatic Osteonecrosis Compared with Healthy Controls

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2018 Jul 7

PMID 29977921

Citations 4

Authors

Biaofang Wei

Wei Wei

Liang Wang

BaoXiang Zhao

Affiliations

Soon will be listed here.

Abstract

Deregulation of microRNAs (miRNAs) contributes to nontraumatic osteonecrosis of the femoral head (ONFH-N), but the differentially expressed circulating miRNAs in patients with ONFH-N receiving nonsurgical therapy are unknown. This study aimed to determine the miRNAs expression profile of patients with ONFH-N receiving conservative treatments. This was a case-control prospective study of 43 patients with ONFH-N and 43 participants without ONFH-N, enrolled from 10/2014 to 10/2016 at the Department of Orthopedics of the Linyi People's Hospital (China). The two groups were matched for age, gender, and living area. Microarray analysis and quantitative RT-PCR were used to examine the differentially expressed miRNAs. Bioinformatics was used to predict miRNA target genes and signaling pathways. Microarray and quantitative RT-PCR revealed that nine miRNAs were downregulated and five miRNAs were upregulated in ONFH-N ( = 3) compared with controls ( = 3). Bioinformatics showed that calcium-mediated signaling pathway, regulation of calcium ion transmembrane transporter activity, cytoskeletal protein binding, and caveolae macromolecular signaling complex were probably regulated by the identified differentially expressed miRNAs. In the remaining 80 subjects ( = 40/group), miR-335-5p was downregulated ( = 0.01) and miR-100-5p was upregulated ( = 0.02) in ONFH-N compared with controls. In conclusion, some miRNAs are differentially expressed in conservatively treated ONFH-N compared with controls. Those miRNAs could contribute to the pathogenesis of ONFH-N.

Citing Articles

Long Noncoding RNA Zinc Finger Antisense 1 Affects Glucocorticoid-Induced Osteonecrosis of the Femoral Head by Performing as a ceRNA for MicroRNA-124-3p and Accelerating Transforming Growth Factor Type III Receptor.

Lan X, Xiong Y, Ma H, Zou L, Yuan Z, Xiao Y Comput Math Methods Med. 2022; 2022:4487864.

PMID: 35898479 PMC: 9313949. DOI: 10.1155/2022/4487864.

Mechanosensitive miR-100 coordinates TGFβ and Wnt signaling in osteocytes during fluid shear stress.

Dole N, Yoon J, Monteiro D, Yang J, Mazur C, Kaya S FASEB J. 2021; 35(10):e21883.

PMID: 34569659 PMC: 9153140. DOI: 10.1096/fj.202100930.

Exosomal miR-100-5p inhibits osteogenesis of hBMSCs and angiogenesis of HUVECs by suppressing the BMPR2/Smad1/5/9 signalling pathway.

Yang W, Zhu W, Yang Y, Guo M, Qian H, Jiang W Stem Cell Res Ther. 2021; 12(1):390.

PMID: 34256859 PMC: 8278698. DOI: 10.1186/s13287-021-02438-y.

[The regulatory role of microRNA in osteogenic differentiation of mesenchymal stem cells and its application as a therapeutic target and diagnostic tool in orthopedic diseases].

Li X, Kong Q Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2020; 34(10):1332-1340.

PMID: 33063501 PMC: 8171876. DOI: 10.7507/1002-1892.201912092.

References

Shuai B, Shen L, Yang Y, Xie J, Shou Z, Wei B . Low plasma adiponectin as a potential biomarker for osteonecrosis of the femoral head. J Rheumatol. 2010; 37(10):2151-5. DOI: 10.3899/jrheum.100342. View

Wu X, Zhang Y, Guo X, Xu H, Xu Z, Duan D . Identification of differentially expressed microRNAs involved in non-traumatic osteonecrosis through microRNA expression profiling. Gene. 2015; 565(1):22-9. DOI: 10.1016/j.gene.2015.03.072. View

Feng B, Wang R, Chen L . MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett. 2011; 317(2):184-91. DOI: 10.1016/j.canlet.2011.11.024. View

Zeng Y, Qu X, Li H, Huang S, Wang S, Xu Q . MicroRNA-100 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells by targeting BMPR2. FEBS Lett. 2012; 586(16):2375-81. DOI: 10.1016/j.febslet.2012.05.049. View

Wang F, Chuang P, Chung P, Lin C, Chen M, Ke H . MicroRNA-29a protects against glucocorticoid-induced bone loss and fragility in rats by orchestrating bone acquisition and resorption. Arthritis Rheum. 2013; 65(6):1530-40. DOI: 10.1002/art.37948. View

. Chinese Guideline for the Diagnosis and Treatment of Osteonecrosis of the Femoral Head in Adults. Orthop Surg. 2017; 9(1):3-12. PMC: 6584093. DOI: 10.1111/os.12302. View

Li Z, Yang B, Weng X, Tse G, Chan M, Wu W . Emerging roles of MicroRNAs in osteonecrosis of the femoral head. Cell Prolif. 2017; 51(1). PMC: 6620832. DOI: 10.1111/cpr.12405. View

Tome M, Lopez-Romero P, Albo C, Sepulveda J, Fernandez-Gutierrez B, Dopazo A . miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ. 2010; 18(6):985-95. PMC: 3131940. DOI: 10.1038/cdd.2010.167. View

Wulfken L, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F . MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One. 2011; 6(9):e25787. PMC: 3184173. DOI: 10.1371/journal.pone.0025787. View

10.

Tornero-Esteban P, Rodriguez-Rodriguez L, Abasolo L, Tome M, Lopez-Romero P, Herranz E . Signature of microRNA expression during osteogenic differentiation of bone marrow MSCs reveals a putative role of miR-335-5p in osteoarthritis. BMC Musculoskelet Disord. 2015; 16:182. PMC: 4526194. DOI: 10.1186/s12891-015-0652-9. View

11.

Choi H, Steinberg M, Cheng E . Osteonecrosis of the femoral head: diagnosis and classification systems. Curr Rev Musculoskelet Med. 2015; 8(3):210-20. PMC: 4596207. DOI: 10.1007/s12178-015-9278-7. View

12.

Yuan H, von Roemeling C, Gao H, Zhang J, Guo C, Yan Z . Analysis of altered microRNA expression profile in the reparative interface of the femoral head with osteonecrosis. Exp Mol Pathol. 2015; 98(2):158-63. DOI: 10.1016/j.yexmp.2015.01.002. View

13.

Wang Y, Cao Y, Li Y, Guo Y, Wang Q, Yang M . Genetic association of the ApoB and ApoA1 gene polymorphisms with the risk for alcohol-induced osteonecrosis of femoral head. Int J Clin Exp Pathol. 2015; 8(9):11332-9. PMC: 4637673. View

14.

Moya-Angeler J, Gianakos A, Villa J, Ni A, Lane J . Current concepts on osteonecrosis of the femoral head. World J Orthop. 2015; 6(8):590-601. PMC: 4573503. DOI: 10.5312/wjo.v6.i8.590. View

15.

Cao H, Guan H, Lai Y, Qin L, Wang X . Review of various treatment options and potential therapies for osteonecrosis of the femoral head. J Orthop Translat. 2018; 4:57-70. PMC: 5987013. DOI: 10.1016/j.jot.2015.09.005. View

16.

Yamasaki K, Nakasa T, Miyaki S, Yamasaki T, Yasunaga Y, Ochi M . Angiogenic microRNA-210 is present in cells surrounding osteonecrosis. J Orthop Res. 2012; 30(8):1263-70. DOI: 10.1002/jor.22079. View

17.

Weilner S, Skalicky S, Salzer B, Keider V, Wagner M, Hildner F . Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. Bone. 2015; 79:43-51. DOI: 10.1016/j.bone.2015.05.027. View

18.

Hernigou P, Poignard A, Nogier A, Manicom O . Fate of very small asymptomatic stage-I osteonecrotic lesions of the hip. J Bone Joint Surg Am. 2004; 86(12):2589-93. DOI: 10.2106/00004623-200412000-00001. View

19.

Scimeca J, Verron E . The multiple therapeutic applications of miRNAs for bone regenerative medicine. Drug Discov Today. 2017; 22(7):1084-1091. DOI: 10.1016/j.drudis.2017.04.007. View

20.

Tripathy S, Goyal T, Sen R . Management of femoral head osteonecrosis: Current concepts. Indian J Orthop. 2015; 49(1):28-45. PMC: 4292325. DOI: 10.4103/0019-5413.143911. View